01In short
Biotech companies are hard to value: much of their worth depends on drugs that haven't been approved yet. I researched U.S. biotech stocks and built models to estimate what they were worth — and what could go wrong.
02What I did
- Researched U.S. biotech equities and developed investment theses that informed a $10K portfolio, which grew 73.9% during the internship.
- Built valuation and scenario models using discounted cash flow (DCF), comparable-company, and risk-adjusted pipeline analyses.
- Assessed each company's commercial upside and key investment risks.
03How I valued a company
Pick one thesis and walk through your reasoning.
04Science meets finance
How did your biology background change how you read a pipeline?